[1] Safiri S, Sullman M, Ashrafi-Asgarabad A.Prognostic value of pathologic grade for patients with oral squamous cell carcinoma[J]. Oral Dis, 2018, 24(5): 868-876. [2] 刘墨, 李劲松, 阮毅, 等. miR-181a抑制舌鳞癌细胞上皮-间充质转化及化疗耐药机制的研究[J]. 中国口腔颌面外科杂志, 2018, 16(4): 289-295. [3] Puram SV, Tirosh I, Parikh AS, et al.Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer[J]. Cell, 2017, 171(7): 1611-1624. [4] Petruzzi MN, Cherubini K, Salum FG, et al.Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge[J]. Diagn Pathol, 2017, 12(1): 32-38. [5] Nagarsheth N, Wicha MS, Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J]. Nat Rev Immunol, 2017, 17(9): 559-572. [6] Lippitz BE.Cytokine patterns in patients with cancer: a systematic review[J]. Lancet Oncol, 2013, 14(6): e218-e228. [7] Yoshimura T, Matsushima K, Oppenheim JJ, et al.Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1(IL 1)[J]. J Immunol, 1987, 139(3): 788-793. [8] 杨蒙, 刘晓斌. 白细胞介素8与肿瘤的研究进展[J]. 中国医药导报, 2016, 13(26): 33-37,47. [9] 肖著军, 许岸高. 白细胞介素8与大肠癌关系的研究进展[J]. 广东医学, 2012, 33(22): 3493-3495. [10] Waugh DJ, Wilson C.The interleukin-8 pathway in cancer[J]. Clin Cancer Res, 2008, 14(21): 6735-6741. [11] Alfaro C, Sanmamed MF, Rodriguez-Ruiz ME, et al.Interleukin-8 in cancer pathogenesis, treatment and follow-up[J]. Cancer Treat Rev, 2017, 60: 24-31. [12] Chan LP, Wang LF, Chiang FY, et al.IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway[J]. Oncotarget, 2016, 7(38): 61820-61831. [13] Christofakis EP, Miyazaki H, Rubink DS, et al.Roles of CXCL8 in squamous cell carcinoma proliferation and migration[J]. Oral Oncol, 2008, 44(10): 920-926. [14] Ha H, Debnath B, Neamati N.Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases[J]. Theranostics, 2017, 7(6): 1543-1588. [15] 姚瑶, 王琳琳. 白细胞介素8研究进展. 实用儿科临床杂志[J]. 2009, 24(10): 789-792. [16] Meniailo ME, Malashchenko VV, Shmarov VA, et al.Direct effects of interleukin-8 on growth and functional activity of T lymphocytes[J]. Int Immunopharmacol, 2017, 50: 178-185. [17] Montaldo E, Vitale C, Cottalasso F, et al.Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor[J]. Blood, 2012, 119(17): 3987-3996. [18] 司马秀山, 李荣哲, 张昕. 白细胞介素8基因在口腔鳞癌中的表达及意义[J]. 口腔颌面外科杂志, 2013, 23(2): 95-97. [19] 冯红超, 彭玉峰, 宋宇峰. 口腔鳞癌中白细胞介素8的表达及临床意义[J]. 贵阳医学院学报, 2008, 33(5), 446-448,452. [20] Miyamoto M, Shimizu Y, Okada K, et al.Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells[J]. Cancer Immunol Immunother, 1998, 47(1): 47-57. [21] Sunaga N, Imai H, Shimizu K, et al.Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer[J]. Int J Cancer, 2012, 130(8): 1733-1744. [22] Huang W, Chen Z, Zhang L, et al.Interleukin-8 induces expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice[J]. Gastroenterology, 2015, 149(4): 1053-1067. [23] Li A, Dubey S, Varney ML, et al.IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis[J]. J Immunol, 2003, 170(6): 3369-3376. [24] Cho BH, Jung YH, Kim DJ, et al.Acetylshikonin suppresses invasion of Porphyromonas gingivalis infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis[J]. Mol Med Rep, 2018, 17(2): 2327-2334. [25] Knall C, Worthen GS, Johnson GL.Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases[J]. Proc Natl Acad Sci, 1997, 94(7): 3052-3057. [26] Cheng GZ, Park S, Shu S, et al.Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery[J]. Curr Cancer Drug Targets, 2008, 8(1): 2-6. [27] Zhang Y, Wang L, Zhang M, et al.Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway[J]. J Cell Physiol, 2012, 227(1): 35-43. [28] 张青云, 傅俊江, 陈汉春. 上皮-间质转化介导肿瘤转移的分子机制[J]. 生命科学研究, 2018, 22(6): 503-510. [29] New J, Arnold L, Ananth M, et al.Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target[J]. Cancer Res, 2017, 77(23): 6679-6691. [30] Gyanchandani R, Sano D, Ortega Alves MV, et al.Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma[J]. Oral Oncol, 2013, 49(8): 761-770. [31] Peng HY, Jiang SS, Hsiao JR, et al.IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma[J]. Mol Oncol, 2016, 10(6): 895-909. [32] Ha NH, Park DG, Woo BH, et al.Porphyromonas gingivalis increases the invasiveness of oral cancer cells by upregulating IL-8 and MMPs[J]. Cytokine, 2016, 86: 64-72. [33] Liu Q, Li A, Tian Y, et al.The CXCL8-CXCR1/2 pathways in cancer[J]. Cytokine Growth Factor Rev, 2016, 31: 61-71. |